Filtered By:
Condition: Cholestasis
Therapy: Gene Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Foxf1 SiRNA Delivery to Hepatic Stellate Cells by DBTC Lipoplex Formulations Ameliorates Fibrosis in Livers of Bile Duct Ligated Mice.
Abstract
Activation of hepatic stellate cells (HSCs) is a key event in pathogenesis of liver fibrosis and represents an orchestral interplay of inhibiting and activating transcription factors like forkhead box f1 (Foxf1), being described to stimulate pro-fibrogenic genes in HSCs. Here, we evaluated a lipid-based liver-specific delivery system (DBTC) suitable to transfer Foxf1 siRNA specifically to HSCs and examined its antifibrotic potential on primary HSCs and LX-2 cells as well as in a murine model of bile duct ligation (BDL)-induced secondary cholestasis. Foxf1 silencing reduced proliferation capacity and atten...
Source: Current Gene Therapy - January 25, 2015 Category: Genetics & Stem Cells Authors: Abshagen K, Brensel M, Genz B, Roth K, Thomas M, Fehring V, Schaeper U, Vollmar B Tags: Curr Gene Ther Source Type: research
